• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Bone invasion-targeted chemotherapy with a novel anionic platinum complex (3Pt) for oral squamous cell carcinoma

Research Project

Project/Area Number 16K11227
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Otorhinolaryngology
Research InstitutionKanazawa University

Principal Investigator

ENDO KAZUHIRA  金沢大学, 附属病院, 助教 (30547154)

Project Period (FY) 2016-04-01 – 2020-03-31
Project Status Discontinued (Fiscal Year 2019)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords頭頸部癌 / シスプラチン / drug delivery system / 化学療法 / パクリタキセル / ミセル
Outline of Final Research Achievements

Cisplatin (CDDP) is an important drug for chemotherapy in patients with head and neck squamous cell carcinoma. To increase its antitumor effect on bone invasion and reduce toxicity problems, anionic Pt complex (3Pt) has been developed. The present study aimed to characterize the basis of the cytotoxicity of the novel platinum complex 3Pt in comparison with that of CDDP . Both 3Pt and CDDP showed equivalent antitumor effects in vivo. Mice injected with CDDP developed renal cell apoptosis; however, those injected with 3Pt were almost free of renal cell injury. In addition to similar in vivo antitumor effects, 3Pt decreased the volume of bone resorption compared to that with CDDP in a bone invasion model using OSC-19. In conclusion, considering the potential advantages in terms of noticeable antitumor activity on bone invasion and reduced nephrotoxicity, 3Pt represents a significant improvement in the development of bone-targeting platinum drug

Academic Significance and Societal Importance of the Research Achievements

頭頸部癌における化学放射線療法は臓器温存の観点からも手術と並んで重要な標準療法の一つである。分子標的薬、免疫チェックポイント阻害剤など多くの薬剤が開発される現在においてもシスプラチンがキードラックの一つである。しかし骨浸潤に対する抵抗性、多くの有害事象が臨床的に問題となっている。こうした背景からdrug delivery systemの観点から、本研究ではリン酸化イオンを結合したシスプラチン(3Pt)を用いて頭頸部癌における有用性を検証した。今回の基礎研究に基づき特に、骨浸潤した症例での有用性が確認できた。今後は本薬剤のヒトにおける安全性、有効性の検証し頭頸部癌治療におけるブレイクスルーとなる

Report

(4 results)
  • 2019 Final Research Report ( PDF )
  • 2018 Annual Research Report
  • 2017 Research-status Report
  • 2016 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi